CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop novel therapeutic agents targeting the Tie2 receptor, which is linked to poor cancer prognosis. It focuses on creating modified angiopoietins to improve cancer imaging and treatment options through enhanced binding and stability.
The dysregulation of cell signaling pathways that mediate proliferation, survival, and migration is an underlying cause of many cancers.
Dysregulation and over-expression of the Tie2 tyrosine kinase receptor, in particular, correlates to a poor prognosis for many human tumors, making Tie2 an attractive target for therapeutic intervention.
Currently no FDA-approved therapeutics targeting the Tie2 receptor exist, and only a few candidate molecules are in early stage clinical trials.
Moreover, dev…
BEN-GURION UNIVERSITY OF THE NEGEV
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
